Abstract
To the Editor.— The design of the Metoprolol Atherosclerosis Prevention in Hypertensives (MAPHY) Study 1 is as unorthodox as the results are surprising. How can deletion of the half of the original cohort from centers not electing to use metoprolol as the β-blocker in the Heart Attack Primary Prevention in Hypertensives (HAPPHY) trial and extension of the period of observation for only 15 months yield findings so disparate from those of the parent HAPPHY trial? If smoking men randomized to metoprolol treatment in the MAPHY Study had a significantly lower mortality rate than those randomized to diuretic treatment, yet in the HAPPHY trial there was no difference in mortality between men taking β-blocker (metoprolol or atenolol) and those taking diuretics, irrespective of smoking habits, it seems inescapable that in the atenolol group that was deleted from the MAPHY Study the mortality rate must have been significantly higher for men taking the
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
